EUVIMEDEUVIMED entdecken
Open Access

Trim38 attenuates pressure overload‑induced cardiac hypertrophy by suppressing the TAK1/JNK/P38 signaling pathway

Yanan Pang, Luyao Wu, Jiachun Xia, Xin Xu, Chenshan Gao, Lei Hou, Li Jiang

International Journal of Molecular Medicine · 28.04.2025 · 55 (6) · 1-15

DOI: 10.3892/ijmm.2025.5539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 28.04.2025. Verfasst von Yanan Pang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Diseases, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China. Hauptthemen laut MEDLINE: Cardiomegaly, MAP Kinase Signaling System, MAP Kinase Kinase Kinases, p38 Mitogen-Activated Protein Kinases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological cardiac hypertrophy is a major contributor to heart failure (HF), resulting in high mortality rates worldwide; therefore, identifying key molecules in pathological cardiac hypertrophy is of critical importance for preventing or reversing HF. Tripartite motif 38 (Trim38) is an E3 ubiquitin ligase that serves a pivotal role in various diseases. The present study aimed to elucidate the regulatory role of Trim38 in pressure overload‑induced pathological cardiac hypertrophy and to explore its underlying molecular mechanisms. The expression of Trim38 was decreased in hypertrophic heart tissues from a murine model of transverse aortic constriction (TAC) and in neonatal rat cardiomyocytes (NRCMs) treated with phenylephrine (PE). Furthermore, Trim38 knockout (Trim38‑KO) aggravated cardiac hypertrophy after TAC, and Trim38 knockdown in cardiomyocytes increased cell cross section area, and upregulated the expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) following treatment with PE. Ubiquitinomics analysis revealed that the MAPK signaling pathway was regulated by Trim38. Furthermore, western blotting confirmed that Trim38‑KO activated TAK1 and JNK/P38. By contrast, Trim38 overexpression in NRCMs suppressed the JNK/P38 signaling pathway and inhibited the phosphorylation of TAK1. Furthermore, Trim38 knockdown resulted in a marked enhancement of TAK1 phosphorylation, concomitant with an augmentation of cardiomyocyte area and a significant upregulation of the hypertrophic biomarkers ANP and BNP. By contrast, infection with an adenovirus containing dominant‑negative TAK1 inhibited TAK1 activity, which attenuated Trim38 knockdown‑induced cardiomyocyte hypertrophy, confirming that TAK1 is a key molecule involved in the protective effects of Trim38 on cardiomyocytes. In conclusion, to the best of our knowledge, the present study is the first to reveal that Trim38 confers protection against pathological cardiac hypertrophy by inhibiting the TAK1/JNK/P38 signaling pathway; therefore, Trim38 may be a promising target for treating cardiac hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomegalyMAP Kinase Signaling SystemMAP Kinase Kinase Kinasesp38 Mitogen-Activated Protein KinasesUbiquitin-Protein LigasesTripartite Motif ProteinsAnimalsMyocytes, CardiacRatsMaleMiceRats, Sprague-DawleySignal TransductionDisease Models, AnimalMice, Inbred C57BLMAP Kinase Kinase Kinase 7

Stichwörter der Autor:innen

JNK/P38 signaling pathwayTAK1Trim38pathological cardiac hypertrophy

Substanzen

MAP Kinase Kinase Kinasesp38 Mitogen-Activated Protein KinasesUbiquitin-Protein LigasesTripartite Motif ProteinsMAP Kinase Kinase Kinase 7

Autor:innen und Institutionen

  • Institute of Cardiovascular Diseases, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China.
  • Division of Cardiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China.
  • Collaborative Innovation Centre of Regenerative Medicine and Medical Bioresource Development and Application Co‑constructed by The Province and Ministry, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
  • Department of Cardiology, Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 201600, P.R. China.

Zitieren

APA

Pang, Y., Wu, L., Xia, J., Xu, X., Gao, C., Hou, L., & Jiang, L. (2025). Trim38 attenuates pressure overload‑induced cardiac hypertrophy by suppressing the TAK1/JNK/P38 signaling pathway. International Journal of Molecular Medicine, 55(6), 1-15. https://doi.org/10.3892/ijmm.2025.5539

Vancouver

Pang Y, Wu L, Xia J, Xu X, Gao C, Hou L, et al. Trim38 attenuates pressure overload‑induced cardiac hypertrophy by suppressing the TAK1/JNK/P38 signaling pathway. International Journal of Molecular Medicine. 2025;55(6):1-15. doi:10.3892/ijmm.2025.5539

BibTeX
@article{Pang2025,
  author = {Pang, Yanan and Wu, Luyao and Xia, Jiachun and Xu, Xin and Gao, Chenshan and Hou, Lei and Jiang, Li},
  title = {Trim38 attenuates pressure overload‑induced cardiac hypertrophy by suppressing the TAK1/JNK/P38 signaling pathway},
  journal = {International Journal of Molecular Medicine},
  year = {2025},
  volume = {55},
  number = {6},
  pages = {1--15},
  doi = {10.3892/ijmm.2025.5539}
}
Kostenlos starten →